18+

Research Use Only — Adults 18+ Only. All products sold by PepHQ, LLC are for research, laboratory, and analytical purposes only. Not intended for human consumption, therapeutic use, or medical application. By continuing to browse, you confirm you are 18 or older and agree to our Terms of Use.

GLP-3 RT 20mg Vial with High Quality Badge

GLP-3 RT 20mg

Triple receptor metabolic research peptide

$108.00per vial
$102.60 per vial for 3-4 vials (5% off)
$97.20 per vial for 5-9 vials (10% off)
$91.80 per vial for 10-19 vials (15% off)
$86.40 per vial for 20-49 vials (20% off)
$81.00 per vial for 50+ vials (25% off)
Purity: 99.927% — Third-Party Verified
Third-party tested via HPLC-UV-MS
Ships within 1-3 business days
Free shipping on orders over $200

Questions About This Product?

Not sure if this is right for your research? Our team is here to help.

Certificate of Analysis

Issued by Freedom Diagnostics — Independent USA Laboratory

Download COA (PDF)
Purity Result
99.927%
HPLC/UV + Mass Spec
Testing Lab
Freedom Diagnostics
USA — Proudly Owned & Operated
COA Number
2602240055
Reported: 2/25/2026
Identity
GLP RT
Confirmed via LCMS/MS

All chemical analysis performed by HPLC with UV Detection Coupled with Mass Spectrometry. Searchable at FreedomDiagnosticsTesting.com using accession number 2602240055.

How It Works

GLP3-R works by simultaneously activating three important hormone receptors: GLP-1, GIP, and glucagon receptors, creating a comprehensive metabolic response that surpasses single-pathway approaches.

Triple-Receptor Activation

GLP-1 Receptor

Triggers insulin release when blood sugar is high, slows stomach emptying, and reduces appetite signals.

GIP Receptor

Enhances insulin response and influences fat metabolism pathways for improved metabolic efficiency.

Metabolic Benefits

Glucagon Receptor

Helps the body burn stored fat for energy and maintains healthy blood sugar levels between meals.

Synergistic Effect

The triple-action approach creates a comprehensive metabolic response more effective than single-pathway targeting.

Research Findings

Preclinical research has demonstrated GLP3-R's remarkable potential across multiple metabolic research domains, showing superior outcomes compared to single-receptor approaches.

Weight Management Studies

Preclinical research has demonstrated significant weight reduction in laboratory models with dose-dependent effects and synergistic triple-receptor mechanisms.

  • Significant weight reduction in laboratory models
  • Dose-dependent effects with higher doses showing greater outcomes
  • Synergistic effects surpassing single or dual-receptor agonists
  • Sustained weight management over extended periods

Metabolic Health Research

Laboratory investigations have revealed comprehensive improvements across multiple metabolic markers and pathways in research models.

  • Enhanced glucose homeostasis and insulin sensitivity
  • Improved lipid profiles in research models
  • Reduced inflammatory markers
  • Better energy expenditure patterns

Comparative Studies

When compared to other GLP-1 receptor agonists, GLP3-R has demonstrated superior outcomes in weight reduction and metabolic improvements.

  • Superior weight reduction compared to single-receptor compounds
  • Enhanced metabolic improvements beyond GLP-1 alone
  • Addition of GIP and glucagon activation provides unique benefits
  • Improved therapeutic potential in research settings

Clinical Translation Research

Phase 2 trials have shown promising results for obesity and type 2 diabetes applications with significant clinical improvements.

  • Phase 2 trial results showing substantial weight loss
  • Improved glycemic control in diabetes research
  • Cardiovascular and metabolic benefits
  • Potential for transforming metabolic disorder treatment

Storage Guidelines

Lyophilized peptides are stable at room temperature for several weeks when stored in a dry, sealed container away from light and moisture.

For extended storage, refrigeration (2-8°C) or freezing (-20°C) is recommended.

All products sold for research use only.

Recent Research (2024-2026)

Latest peer-reviewed publications on triple receptor agonists for laboratory research applications.

Triple Receptor Agonism in Obesity Pharmacotherapy

PMC, May 2025

Comprehensive review of novel triple receptor agonists targeting GLP-1, GIP, and glucagon receptors. Discusses mechanisms of action and potential research applications in metabolic studies.

View Publication →

Lilly's TRIUMPH-4 Phase III Trial Results

Clinical Trials Arena, December 2025

Phase III clinical trial data demonstrating efficacy of triple glucagon agonist in research settings. Provides insights into dosing protocols and outcome measurements for laboratory studies.

View Publication →

Cardiovascular Outcomes of Semaglutide and Tirzepatide

Nature, November 2025

Cohort studies assessing effectiveness and safety profiles in research models. Valuable data for researchers designing cardiovascular-related metabolic studies.

View Publication →

IMPORTANT: This product is exclusively for laboratory research purposes and is not approved for human or veterinary use.